Shatterproof Statement on the Passage of the Big Beautiful Bill
At the same time, we are deeply concerned about the bill's potential impact on access to treatment for individuals living with substance use disorder (SUD). Medicaid is the nation's single largest payer of addiction treatment services—serving a population in which 21% are impacted by SUD, compared to 16% of those with commercial insurance.
The impact on Medicaid is likely to have a harmful ripple effect across the healthcare system. At a time when overdoses remain at crisis levels, states need greater – not fewer – resources to meet the critical needs of families and communities to prevent and treat SUD. In 2024, nearly 250,000 deaths were attributed to overdoses and/or alcohol use disorder, in addition to untold societal and economic costs.
Shatterproof remains committed to ensuring individuals and families affected by addiction have access to evidence-based, lifesaving care. We urge Congress to prioritize support for essential infrastructure during the FY2026 appropriations process, including support for the National Survey on Drug Use and Health and funding to improve findtreatment.gov, the national treatment locator, by incorporating meaningful quality metrics.
Shatterproof stands as a nonpartisan, evidence-driven resource committed to supporting those affected by addiction and creating a more resilient nation.
About Shatterproof
Shatterproof is a national nonprofit organization dedicated to reducing the burden of substance use disorder in
View original content to download multimedia:https://www.prnewswire.com/news-releases/shatterproof-statement-on-the-passage-of-the-big-beautiful-bill-302497973.html
SOURCE Shatterproof
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ANAC Publishes Proposed Noise Certification Criteria for Eve 100
- Eve Air Mobility and Moov Sign LOI for up to 30 eVTOLs to Explore Tourism and Regional Mobility in Cabo Verde
- REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share